Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides|
|Abstract:||The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.|
|Inventor(s):||von Borstel; Reid W. (Potomac, MD), Bamat; Michael K. (Potomac, MD)|
|Assignee:||Wellstat Therapeutics Corporation (Gaithersburg, MD)|
1. A method for treating toxicity due to a pyrimidine nucleoside analog in an animal comprising administering to said animal a pharmaceutically effective amount of an
acylated derivative of uridine or cytidine selected from the group consisting of triacetyluridine and ethoxycarbonyluridine or triacetylcytidine, wherein said pyrimidine nucleoside analog is selected from the group consisting of 5-fluorouracil (5-FU),
Tegafur, 5-fluoroorotate, 5'-deoxy-5-fluorouridine, 5-fluorouridine, 2'-deoxy-5-fluorouridine, fluorocytosine, trifluoromethyl-2'-deoxyuridine, arabinosyl cytosine, cyclocytidine, 5-aza-2'-deoxycytidine, arabinosyl 5-azacytosine, 6-azacytidine,
N-phosphonoacetyl-L-aspartic acid (PALA), pyrazofurin, 6-azauridine, azaribine, thymidine, 3-deazauridine, AZT, dideoxycytidine, 5-ethyl-2'-deoxyuridine, 5-iodo-2'deoxyuridine, 5-bromo-2'-deoxyuridine, 5-methylamino-2'-deoxyuridine, arabinosyluracil,
dideoxyuridine and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine; and wherein said toxicity is selected from the group consisting of damage to hematopoietic tissue and damage to mucosal tissues.
2. A method as in claim 1 wherein said toxicity is damage to hematopoietic tissue.
3. A method as in claim 1 wherein said toxicity is damage to mucosal tissues.
4. A method as in claim 1 wherein said administering step also includes administering an inhibitor of uridine phosphorylase selected from the group consisting of benzylacyclouridine, benzyloxybenzylacyclo-uridine, aminomethyl-benzylacyclouridine, aminomethyl-benzyloxybenzylacyclo-uridine, hydroxymethyl-benzylacyclouridine, hydroxymethyl-benzyloxybenzylacyclouridine, 2,2'-anhydro-5-ethyluridine, 5-benzyl barbiturate, 5-benzyloxybenzyl barbiturate, 5-benzyloxybenzyl-1-[(1-hydroxy-2-ethoxy)methyl]barbiturate, 5-benzyloxybenzylacetyl-1-[(1-hydroxy-2-ethoxy)methyl]barbiturate, and 5-methoxybenzylacetylacyclobarbiturate.
5. A method as in claim 1 wherein said acylated derivative is triacetylcytidine, and said administering step also includes administering an inhibitor of cytidine deaminase selected from the group consisting of tetrahydrouridine and tetrahydro-2'-deoxyuridine.
6. A method as in claim 1 wherein said administering step also includes administering an inhibitor of nucleoside transport selected from the group consisting of dipyridamole, probenicid, lidoflazine and nitrobenzylthioino sine.
7. A method as in claim 1 wherein said administering step also includes administering an agent which enhances hematopoiesis selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, stem cell factor, erythropoietin, glucan, and polyinosine-polycytidine.
8. A method as in claim 1 wherein said administering step also includes administering a compound capable of enhancing the uptake and phosphorylation of nucleosides into cells selected from the group consisting of insulin and insulinogenic carbohydrate.
9. A method as in claim 1, wherein said acylated derivative of uridine is triacetyluridine.
10. A method as in claim 9, wherein said pyrimidine nucleoside analog is 5-fluorouracil (5-FU).
11. A method as in claim 9, wherein said pyrimidine nucleoside analog is AZT and said toxicity is damage to hematopoietic tissue.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.